Counseling and surveillance of obstetrical risks for female childhood, adolescent, and young adult cancer survivors: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group.

Female childhood, adolescent, and young adult cancer survivors have an increased risk of adverse pregnancy outcomes related to their cancer- or treatment-associated sequelae. Optimal care for childhood, adolescent, and young adult cancer survivors can be facilitated by clinical practice guidelines that identify specific adverse pregnancy outcomes and the clinical characteristics of at-risk subgroups. However, national guidelines are scarce and vary in content. Here, the International Late Effects of Childhood Cancer Guideline Harmonization Group offers recommendations for the counseling and surveillance of obstetrical risks of childhood, adolescent, and young adult survivors. A systematic literature search in MEDLINE database (through PubMed) to identify all available evidence published between January 1990 and December 2018. Published articles on pregnancy and perinatal or congenital risks in female cancer survivors were screened for eligibility. Study designs with a sample size larger than 40 pregnancies in childhood, adolescent, and young adult cancer survivors (diagnosed before the age of 25 years, not pregnant at that time) were eligible. This guideline from the International Late Effects of Childhood Cancer Guideline Harmonization Group systematically appraised the quality of available evidence for adverse obstetrical outcomes in childhood, adolescent, and young adult cancer survivors using Grading of Recommendations Assessment, Development, and Evaluation methodology and formulated recommendations to enhance evidence-based obstetrical care and preconception counseling of female childhood, adolescent, and young adult cancer survivors. Healthcare providers should discuss the risk of adverse obstetrical outcomes based on cancer treatment exposures with all female childhood, adolescent, and young adult cancer survivors of reproductive age, before conception. Healthcare providers should be aware that there is no evidence to support an increased risk of giving birth to a child with congenital anomalies (high-quality evidence). Survivors treated with radiotherapy to volumes exposing the uterus and their healthcare providers should be aware of the risk of adverse obstetrical outcomes such as miscarriage (moderate-quality evidence), premature birth (high-quality evidence), and low birthweight (high-quality evidence); therefore, high-risk obstetrical surveillance is recommended. Cardiomyopathy surveillance is reasonable before pregnancy or in the first trimester for all female survivors treated with anthracyclines and chest radiation. Female cancer survivors have increased risks of premature delivery and low birthweight associated with radiotherapy targeting the lower body and thereby exposing the uterus, which warrant high-risk pregnancy surveillance.

Adverse perinatal outcomes are more frequent in pregnancies with a low fetal fraction result on noninvasive prenatal testing.

OBJECTIVE: This study aimed to assess risk of an adverse perinatal outcome for women with a low fetal fraction (LFF) result on noninvasive prenatal testing (NIPT). STUDY DESIGN: A retrospective cohort study whereby women with an LFF result were compared with women who had a sufficient fetal fraction (SFF) result on NIPT. Inclusion criteria were singleton pregnancies with quantification of fetal fraction and pregnancy outcome information. Primary outcome was a composite of any of the following: miscarriage, fetal demise, neonatal death, preterm birth, pregnancy-associated hypertensive disorder, placental abruption, and low birth weight. RESULTS: Three hundred forty-eight (94%) women had an SFF result, and 22 (6%) women had an LFF result. The mean gestational age at the time of NIPT was comparable for both groups. Women with an LFF result were more likely to be African American (86% vs 52%; p = 0.007) and have a higher body mass index (BMI) (mean BMI = 37 kg/m(2) vs BMI = 29 kg/m(2) ; p ≤ 0.001) than women with an SFF result. The composite outcome was significantly more common in the LFF group (59.1% vs 29%; p = 0.003). After adjusting for race and BMI, LFF remained independently associated with adverse perinatal outcome with adjusted odds ratio = 2.5 (95% confidence interval 1.01-6.2; p = 0.049). CONCLUSIONS: Women with an LFF result have an increased likelihood of an adverse pregnancy outcome.

Can the quantity of cell-free fetal DNA predict preeclampsia: a systematic review.

OBJECTIVE: Previous studies have demonstrated an increase in the quantity of cell-free fetal DNA (cffDNA) before the onset of preeclampsia. It would be beneficial if the quantity of cffDNA predicted preeclampsia in order to implement preventative trials and strategies to decrease maternal and fetal morbidity. Our objective was to review the literature on using cffDNA levels as a predictor of preeclampsia. METHODS: We performed a systematic review following the Meta-analyses and Systematic Review of Observational Studies guidelines. Included studies evaluated cffDNA levels in pregnant women before the clinical onset of preeclampsia. RESULTS: Thirteen studies met inclusion criteria. There was considerable heterogeneity between included studies, and all received a quality grade of C on the Grading of Recommendations Assessment, Development, and Evaluation scale. Of the 13 studies, 11 found an increase in cffDNA among pregnant women who subsequently developed preeclampsia. In addition, all four studies analyzing early-onset or severe preeclampsia found significantly elevated cffDNA levels prior to disease onset. CONCLUSION: Cell-free fetal DNA quantification is a promising marker for preeclampsia prediction, especially for the development of early-onset or severe preeclampsia. However, because of the heterogeneity in published studies, a precise conclusion about the statistical and clinical relevance cannot be made.

Fraction of cell-free fetal DNA in the maternal serum as a predictor of abnormal placental invasion-a pilot study.

OBJECTIVE: Pilot studies have suggested the amount of cell-free fetal DNA (cffDNA) in the maternal serum is increased in pregnancies complicated by placenta accreta. Our objective was to determine if levels of cffDNA can predict invasive placentation. METHODS: We enrolled women with antenatally suspected placenta accreta compared with gestational age-matched cases of placenta previa and women with prior cesarean deliveries (CDs) and normal placentation. The fetal fraction of cffDNA was quantified using DANSR™ as compared with total DNA. Patient characteristics were compared between the three groups using ANOVA, and linear regression was used to compare the fraction of cffDNA between pathologically confirmed cases of placenta accreta, placenta previa and normal placentation. RESULTS: Twenty women were enrolled, (seven cases of placenta accreta, six cases of placenta previa and seven cases of normal placentation with prior CD). The groups did not differ by maternal weight, placental weight, number of prior CD or years from prior CD. The mean fraction of cffDNA did not differ significantly by group when controlling for the aforementioned factors (accreta = 19.1%, previa = 27.2%, prior CD = 28.9%, p = 0.26), nor did the median (accreta = 17.0%, previa = 30.1%, prior CD = 22.7%). CONCLUSIONS: We could not confirm diagnostic benefit. Further investigation of other biomarkers including placental mRNA is warranted.

What's trending? Reach and content of the Society for Maternal-Fetal Medicine on social media.

BACKGROUND: The Society for Maternal-Fetal Medicine uses social media to increase awareness of the Society and its key programs and to foster community and discussion around perinatal health, especially on Twitter. The influence and role of the Society for Maternal-Fetal Medicine Twitter account in public discourse around issues relevant to pregnancy have not been studied. OBJECTIVE: This study aimed to evaluate the trends in engagement with the Society for Maternal-Fetal Medicine on Twitter by analyzing Society for Maternal-Fetal Medicine follower growth and discussion topics on Twitter compared with Facebook and by quantifying public engagement during the Society for Maternal-Fetal Medicine Annual Pregnancy Meeting. STUDY DESIGN: This retrospective study analyzed follower growth data from August 2019 to July 2022 for the Society for Maternal-Fetal Medicine Twitter (@MySMFM) and Society for Maternal-Fetal Medicine Facebook (@SocietyforMaternalFetalMedicine) accounts. We identified the top 10 tweets and Facebook posts during the study period using Twitter Analytics and Facebook data. The popularity of tweets and Facebook posts was determined by "impressions" and "reach," respectively; these metrics reflect the number of times a post was viewed. To evaluate annual trends in Society for Maternal-Fetal Medicine Twitter engagement, we analyzed data associated with the Society for Maternal-Fetal Medicine Annual Pregnancy Meeting, including the number of tweets using the hashtag (#SMFM(Year)) and overall impressions for the Society for Maternal-Fetal Medicine Twitter account for each meeting from 2016 to 2023. RESULTS: The absolute number of new followers for the Society for Maternal-Fetal Medicine Twitter and Facebook accounts was similar, but the relative increase and rate of follower growth was higher for Twitter than for Facebook. The Twitter account consistently gained followers, whereas the Facebook account experienced intermittent periods of stagnancy or follower loss. More than half of the top-ranked posts on Twitter and Facebook mentioned the COVID-19 vaccine; other popular topics included COVID-19 and abortion. During the Society for Maternal-Fetal Medicine Annual Pregnancy Meeting, the number of tweets using the meeting hashtag consistently peaked on meeting day 4, coincident with the opening plenary session (mean 1270±499). An upward trend in annual pregnancy meeting tweets was observed each year until 2021-the first virtual Society for Maternal-Fetal Medicine meeting. CONCLUSION: The trends in Society for Maternal-Fetal Medicine Twitter engagement suggest increasing use and popularity of the platform for timely dissemination of pregnancy-related news, guidelines, and research. The reduction in annual pregnancy meeting tweets and impressions in 2021 and 2022 suggests the potential negative effect of virtual meetings on Society for Maternal-Fetal Medicine member engagement around annual meeting content.

Clinical indications for abnormal early gestational 50-g glucose tolerance testing.

Providers occasionally screen women thought to be at particularly increased risk of gestational diabetes mellitus (GDM) with a first- or second-trimester ("early") glucose tolerance test (GTT). We sought to describe how the frequency of abnormal early GTT varies by indication for testing. This is a retrospective cohort study of women receiving prenatal care in our clinic who underwent a 50-g GTT at less than 24 weeks between 2003 and 2006. Three hundred five women received an early GTT. The most common indications for early screening were obesity (53%), family history of diabetes (15%), prior history of GDM (10%), and multifetal gestation (5%). The frequency of abnormal testing in patients with multifetal gestations and a personal history of GDM was higher than in those undergoing early testing because of obesity. The frequency of abnormal early GTT varies by indication for testing. These data may be used in the allocation of health care resources.

Metastatic ovarian serous carcinoma presenting as inflammatory breast cancer: a case report.

A 42-year-old woman presented with localized irritation, erythema and sharp pain in the one breast. After unsuccessful treatment for mastitis, an oncology consultation was obtained. A breast biopsy revealed an invasive carcinoma and a diagnosis of inflammatory breast cancer was made. The patient was treated with neo-adjuvant chemotherapy and subsequently underwent bilateral mastectomy. A total abdominal hysterectomy and bilateral salpingo-oophorectomy was also performed at the same time due to the presence of a pelvic mass. Morphologic and immunohistochemical examination of the specimens helped to clarify the correct diagnosis of primary ovarian carcinoma with widespread metastases to bilateral breasts.

Evaluation of a novel screening method for fetal aneuploidy using cell-free DNA in maternal plasma.

Objective: To evaluate the test performance of a novel sequencing technology using molecular inversion probes applied to cell-free DNA screening for fetal aneuploidy. Methods: Two cohorts were included in the evaluation; a risk-based cohort of women receiving diagnostic testing in the first and second trimesters was combined with stored samples from pregnancies with fetuses known to be aneuploid or euploid. All samples were blinded to testing personnel before being analyzed, and validation occurred after the study closed and results were merged. Results: Using the new sequencing technology, 1414 samples were analyzed. The findings showed sensitivities and specificities for the common trisomies and the sex chromosome aneuploidies at >99% (Trisomy 21 sensitivity 99.2 CI 95.6­99.2; specificity 99.9 CI 99.6­99.9). Positive predictive values among the trisomies varied from 85.2% (Trisomy 18) to 99.0% (Trisomy 21), reflecting their prevalence rates in the study. Comparisons with a meta-analysis of recent cell-free DNA screening publications demonstrated equivalent test performance. Conclusion: This new technology demonstrates equivalent test performance compared with alternative sequencing approaches, and demonstrates that each chromosome can be successfully interrogated using a single probe.

Bacillus Calmette-Guérin vaccine-induced lupus vulgaris in a child adopted from China.

Lupus vulgaris is a rare form of cutaneous mycobacterial infection that can occur from mycobacterial exposure and even more rarely from exposure to the Bacillus Calmette-Guérin vaccine. We report a child who received this vaccination in China and then developed lupus vulgaris shortly after being adopted in the United States. After histopathologic confirmation, the infection was successfully treated with a combination of antibiotics. This occurrence demonstrates the need for heightened surveillance of Bacillus Calmette-Guérin vaccine-induced lupus vulgaris, given the increasing numbers of overseas adoptions taking place in the United States. To our knowledge, this is the first reported instance of Bacillus Calmette-Guérin immunization-induced lupus vulgaris in the United States.

The effect of chorionic villus sampling on the fraction of cell-free fetal DNA in maternal plasma.

OBJECTIVE: This study aims to assess whether the fraction of cell-free fetal DNA (cffDNA) is different at 24 h or 7 days after chorionic villus sampling (CVS), compared to subjects that do not undergo CVS. METHODS: Pregnant women undergoing CVS for genetic testing and matched subjects undergoing first trimester combined screening alone were enrolled between 11(0/7) and 13(6/7) weeks gestation. The fractions of cffDNA were compared before the procedure, 24 h after and 7 days after between CVS patients and ultrasound-only patients. RESULTS: Forty-five women underwent CVS and 45 had ultrasound alone. The women undergoing CVS were, on average, older (36.8 years versus 28.5 years, p=0.001) and had a higher baseline fraction of cffDNA than women in the comparison group (11.4% versus 9.8%, p=0.033). Both groups had a decrease in the mean fraction of cffDNA after 24 h. After 7 days, the trend of the mean fraction of cffDNA continued to decline in the CVS group but began to trend toward an increase in the ultrasound only group. CONCLUSIONS: CVS does not significantly increase the fraction of cell free fetal (placental) DNA in the maternal plasma. A downward trend in cffDNA in maternal plasma is seen at 24 h and 7 days following CVS compared to baseline.

Expectant management of preeclampsia superimposed on chronic hypertension.

OBJECTIVE: Women with chronic hypertension (CHTN) are at an increased risk for pregnancy complications including preeclampsia. The objective of this study was to review pregnancy outcomes for women with expectant management of preeclampsia superimposed on CHTN prior to 37 weeks'. METHODS: We reviewed the inpatient charts of all women admitted to Magee-Womens Hospital (1995-2005) with the diagnosis of both CHTN and preeclampsia prior to term. RESULTS: Sixty-eight women diagnosed with both CHTN and preeclampsia prior to 37 weeks' were identified. Of these, 42 women were expectantly managed; one subject was excluded from analysis for pregestational diabetes. For the remaining 41 women, the median gestational age at diagnosis was 31.6 weeks (range 23.6-36.4). The mean time from diagnosis to delivery was 9.7 days (range 2-34 days). Adverse perinatal outcomes included one case of HELLP syndrome, two cases of placental abruptions, three cases of pulmonary edema, and five postpartum hemorrhages. There were no fetal/neonatal or maternal deaths. Average NICU stay was 17.9 days. CONCLUSIONS: Expectant management of preterm superimposed preeclampsia among women with CHTN is a reasonable management strategy, but associated with some maternal morbidity. Prospective studies are needed to definitively quantify the risks and benefits of this approach.

Avoiding treatment of leiomyosarcomas: the role of magnetic resonance in focused ultrasound surgery.

OBJECTIVE: To report early diagnosis of a uterine leiomyosarcoma during screening for magnetic resonance imaging-guided focused ultrasound surgery (MRgFUS) for leiomyomas. DESIGN: Case report. SETTING: University hospital conducting an institutional review board-approved clinical trial. PATIENT(S): A 47-year-old premenopausal woman with presumed symptomatic leiomyomas for 5 years and minimal interval growth. INTERVENTION(S): Magnetic resonance imaging screening protocol used as a routine part of MRgFUS treatment protocol. MAIN OUTCOME MEASURE(S): Surgical pathology report. RESULT(S): The diagnosis of leiomyosarcoma was suspected at the time of screening, and inadvertent treatment of a leiomyosarcoma was avoided. The patient underwent hysterectomy performed by her referring physician and confirmed the diagnosis of leiomyosarcoma. CONCLUSION(S): The possibility of inadvertent treatment of malignant disease and thus delayed diagnosis exists with all non-excisional therapies for uterine leiomyomas. The pretreatment imaging before MRgFUS in this case led to an expedited diagnosis of malignancy. Although this did not lead to a change in prognosis for this patient, careful review of magnetic resonance imaging before MRgFUS may allow early diagnosis for uterine malignancies.